Core Viewpoint - Maravai LifeSciences Holdings, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 7, 2024, and February 24, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is alleged that the Company inaccurately recognized revenue on certain transactions during fiscal 2024, leading to an overstatement of goodwill [2] - Defendants' positive statements regarding the Company's business, operations, and prospects are claimed to be materially misleading and lacking a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until May 5, 2025, to request appointment as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - A securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial reporting during the Class Period from August 7, 2024, to February 24, 2025 [1] Group 1: Allegations Against Maravai - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2] - It is alleged that Maravai inaccurately recognized revenue on certain transactions during fiscal 2024 [2] - The complaint states that Maravai's goodwill was overstated, leading to materially misleading statements about the company's business and prospects [2] Group 2: Lead Plaintiff Process - Investors in Maravai have until May 5, 2025, to seek appointment as a lead plaintiff representative of the class [3] - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3] - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3] Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has recovered billions for victims of corporate misconduct [4] - The firm encourages Maravai investors who have suffered losses to contact them for more information [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Maravai Lifesciences Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on May 5, 2025 [1]. Group 1: Class Action Details - Investors who purchased Maravai securities between August 7, 2024, and February 24, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit claims that Maravai made false or misleading statements regarding its financial reporting and internal controls, leading to inaccurate revenue recognition and overstated goodwill [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Maravai LifeSciences Holdings, Inc. due to allegations of violations of federal securities laws, particularly concerning revenue recognition and internal controls [2][4]. Group 1: Allegations and Financial Impact - The complaint alleges that Maravai and its executives made false or misleading statements and failed to disclose inadequate internal controls over financial reporting related to revenue recognition [4]. - Maravai identified an error in revenue recognition that resulted in approximately $3.9 million being recorded incorrectly, leading to a material weakness in its internal controls [5]. - Following the announcement of these issues, Maravai's share price fell by $0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, with unusually heavy trading volume [6]. Group 2: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $50,000 between August 7, 2024, and February 24, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1]. - There is a deadline of May 5, 2025, for investors to seek the role of lead plaintiff in the federal securities class action filed against Maravai [2][7]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Maravai's conduct [8].

NEW YORK, April 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zl ...

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of the May 5, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired Maravai Lifesciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ:MRVI) securities during the period from August 7, 2024, through February 24, 2025 (“the Class Period”). [LEARN MORE ABOUT THE CLASS ACTION] On February 25, 2025, before the market opened, Maravai ...

RADNOR, Pa., April 10, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against Maravai LifeSciences Holdings, Inc. (“Maravai”) (NASDAQ: MRVI) on behalf of those who purchased or otherwise acquired Maravai securities between August 7, 2024, and February 24, 2025, inclusive (the “Class Period”). The lead plaintiff deadlin ...

RADNOR, Pa., April 10, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. ("Maravai") (NASDAQ: MRVI) on behalf of those who purchased or otherwise acquired Maravai securities between August 7, 2024, and February 24, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is May 5, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Mara ...

NEW YORK, April 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI).Shareholders who purchased shares of MRVI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/maravai-lifesciences-holdings-inc-loss-submission-form/?id=140985&fro ...

Core Viewpoint - A securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly making false and misleading statements regarding its financial reporting and business operations during the specified Class Period from August 7, 2024, to February 24, 2025 [1]. Group 1: Allegations Against Maravai - The complaint alleges that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [3]. - It is claimed that Maravai inaccurately recognized revenue on certain transactions during fiscal 2024 [3]. - The lawsuit also states that Maravai's goodwill was overstated, leading to materially misleading positive statements about the company's business and prospects [3]. Group 2: Legal Process for Investors - Investors in Maravai have until May 5, 2025, to seek appointment as a lead plaintiff representative of the class [4]. - A lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the proposed class [4]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [4].